Search in:

ClinicoEconomics and Outcomes Research Volume 8, 2016 - Issue

Submit an article Journal homepage

Open access

139

Views

CrossRef citations to date

Altmetric

Review

Cost-effectiveness of bortezomib for multiple myeloma: a systematic review

Wendong Chen1 Normin Health, Toronto, ON, CanadaCorrespondence[email protected]

Yicheng Yang2 Xian Janssen, Beijing, People’s Republic of China

Yi Chen3 Normin Health Changsha Representative Office, Changsha, People’s Republic of China

Fen Du3 Normin Health Changsha Representative Office, Changsha, People’s Republic of China

Huan Zhan3 Normin Health Changsha Representative Office, Changsha, People’s Republic of China

Pages 137-151 | Published online: 03 May 2016

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

Citations (10)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Articles from other publishers (10)

Gül Kozalak, İsmail Bütün, Erçil Toyran & Ali Koşar. (2023) Review on Bortezomib Resistance in Multiple Myeloma and Potential Role of Emerging Technologies. Pharmaceuticals 16:1, pages 111.
Crossref

Nicolás Armijo, Manuel Espinoza, Paula Zamorano, Daniela Lahoz, Tamara Yañez & Carlos Balmaceda. (2022) Analisis del proceso de Evaluación de Tecnologías Sanitarias del Sistema de Protección Financiera Para Diagnósticos y Tratamientos de Alto Costo en Chile (Ley Ricarte Soto). Value in Health Regional Issues 32, pages 95-101.
Crossref

Jeng-Shiun Du, Yi-Chun Kuo, Hon-Yi Shi, Ming-Chung Wang, Li-Ying Wang, Tzer-Ming Chuang, Ya-Lun Ke, Tsung-Jang Yeh, Yu-Ching Gau, Hui-Ching Wang, Shih-Feng Cho, Samuel Yien Hsiao, Yi-Chang Liu, Chin-Mu Hsu & Hui-Hua Hsiao. (2022) The Cost-Effectiveness Analysis of Transplant-Ineligible Myeloma Patients with Bortezomib plus Thalidomide plus Dexamethasone (VTD) or Bortezomib plus Melphalan plus Prednisolone (VMP) Treatment in Southern Taiwan. Journal of Personalized Medicine 12:2, pages 130.
Crossref

Sipho Mdanda, Philemon Ubanako, Pierre P. D. Kondiah, Pradeep Kumar & Yahya E. Choonara. (2021) Recent Advances in Microneedle Platforms for Transdermal Drug Delivery Technologies. Polymers 13:15, pages 2405.
Crossref

Matteo Franchi, Claudia Vener, Donatella Garau, Ursula Kirchmayer, Mirko Di Martino, Marilena Romero, Ilenia De Carlo, Salvatore Scondotto, Chiara Stival, Matteo Giovanni Della Porta, Francesco Passamonti & Giovanni Corrao. (2021) Bortezomib-based therapy in non-transplant multiple myeloma patients: a retrospective cohort study from the FABIO project. Therapeutic Advances in Hematology 12, pages 204062072199648.
Crossref

Crystal Loke, Peter Mollee, Ian McPherson, Euan Walpole, Mimi Yue, Howard Mutsando, Phillip Wong, Helen Weston, Ross Tomlinson & Samantha Hollingworth. (2020) Bortezomib use and outcomes for the treatment of multiple myeloma. Internal Medicine Journal 50:9, pages 1059-1066.
Crossref

Đurđa Vukićević, Ursula Rochau, Aleksandar Savić, Monika Schaffner, Milica Jevđević, Igor Stojkov, Gaby Sroczynski, Wolfgang Willenbacher, Beate Jahn & Uwe Siebert. (2020) Long-Term Effectiveness and Cost Effectiveness of Multiple Myeloma Treatment Strategies for Elderly Transplant-Ineligible Patients in Serbia. Slovenian Journal of Public Health 59:2, pages 83-91.
Crossref

Shuangshuang Fu, Chi-Fang Wu, Michael Wang & David R. Lairson. (2019) Cost Effectiveness of Transplant, Conventional Chemotherapy, and Novel Agents in Multiple Myeloma: A Systematic Review. PharmacoEconomics 37:12, pages 1421-1449.
Crossref

Roberto José Pessoa de Magalhães Filho, Edvan Crusoe, Eloisa Riva, Willen Bujan, Guilhermo Conte, Juan Ramon Navarro Cabrera, Diana Katerine Garcia, Guilhermo Quintero Vega, Jose Macias, Jose Willian Oliveros Alvear, Mercedes Royg, Lidiane Andino Neves, Jose Luis Lopez Dopico, German Espino, Douglas Rosales Ortiz, Zurelis Socarra, Dorotea Fantl, Guillermo J. Ruiz-Arguelles, Angelo Maiolino, Vania Tietsche de Moraes Hungria, Jean-Luc Harousseau & Brian Durie. (2019) Analysis of Availability and Access of Anti-myeloma Drugs and Impact on the Management of Multiple Myeloma in Latin American Countries. Clinical Lymphoma Myeloma and Leukemia 19:1, pages e43-e50.
Crossref

David MerolaCandice YongStephen J. NogaKenneth M. Shermock. (2018) Costs Associated with Productivity Loss Among U.S. Patients Newly Diagnosed with Multiple Myeloma Receiving Oral Versus Injectable Chemotherapy. Journal of Managed Care & Specialty Pharmacy 24:10, pages 1019-1026.
Crossref

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Cost-effectiveness of bortezomib for multiple myeloma: a systematic review

Articles from other publishers (10)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Cost-effectiveness of bortezomib for multiple myeloma: a systematic review

Citations (10)

Articles from other publishers (10)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date